TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 4.4% from a year ago
Net receivables stood at $5.22M at the end of Q1 FY2026, down 4.4% from a year earlier and down 20.5% from the prior quarter. Over 3 fiscal years it compounded at +61.5% a year.
Context
- Net receivables amounted to 7.3% of total assets at the end of Q1 FY2026, down 11.7 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -4.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 6.56M USD
- Year-over-year change
- +28.9%
- 4-year CAGR
- +48.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.56M | +28.9% |
| FY2024 | 2024-12-31 | 5.09M | +43.1% |
| FY2023 | 2023-12-31 | 3.55M | +128.3% |
| FY2022 | 2022-12-31 | 1.56M | +14.7% |
| FY2021 | 2021-12-31 | 1.36M | — |
Net Receivables vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's Mar 2026 net receivables of $5.22M is the 5th highest of the 11 companies compared; the peer median is $4.71M.
- Its year-over-year change of -4.4% is the 6th highest of 11, against a peer median of -9.5%.
- Net receivables amounts to 7.3% of total assets for TLSI, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $19.86M | +20.2% | +12.8% | 22.9% | |
| Mar 2026 | $16.21M | -39.7% | +6.9% | 12.9% | |
| Mar 2026 | $11.88M | +4.2% | -58.8% | 6.8% | |
| Mar 2026 | $9.45M | +58.5% | +15.8% | 12.8% | |
| Mar 2026 | $5.22M | -4.4% | +61.5% | 7.3% | |
| Mar 2026 | $5.18M | -28.4% | +0.7% | 7.8% | |
| Mar 2026 | $4.25M | -23.1% | -32.1% | 2.2% | |
| Dec 2025 | $2.01M | +11.5% | +27.2% | 1.2% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $231K | +22.2% | -72.4% | 0.1% |
| Mar 2026 | $58K | -25.6% | -83.6% | 0.0% | |
| Mar 2026 | $47K | -80.3% | -37.5% | 0.1% | |
| Peer median (excluding TLSI) | $4.71M | -9.5% | -15.7% | 4.5% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.3M | 9.41M | 11.78M | 8.53M | 20.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.36M | 1.56M | 3.55M | 5.09M | 6.56M |
| Inventory | 1.29M | 1.47M | 2.55M | 4.05M | 3.08M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 35.13M | 17.21M | 20.86M | 20.67M | 32.24M |
| Property, Plant & Equipment (Net) | 1.8M | 3.61M | 3.27M | 2.88M | 2.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 794K | 802K | 0 | 0 | 0 |
| Long-term Investments | 0 | 250K | 0 | 350K | 400K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115K | 117K | 466K | 73K | 18K |
| Total Non-current Assets | 2.71M | 4.78M | 3.74M | 3.3M | 3.09M |
| Total Assets | 37.84M | 22M | 24.6M | 23.97M | 35.33M |
| Account Payables | 1.3M | 4.95M | 3.39M | 2.27M | 3M |
| Short-term Debt | 0 | 370K | 0 | 0 | 167K |
| Tax Payables | 0 | 0 | 0 | 34K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 104K | 23.57M | 420K | 383K | 8.23M |
| Total Current Liabilities | 6.37M | 32.36M | 14.69M | 10.23M | 11.5M |
| Long-term Debt | 0 | 0 | 0 | 22.08M | 34.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 561K | 369K | 35.73M | 16.22M | 23.42M |
| Total Non-current Liabilities | 561K | 1.96M | 36.98M | 39.64M | 57.69M |
| Total Liabilities | 6.93M | 34.32M | 51.66M | 49.87M | 69.19M |
| Common Stock | 11K | 0 | 2K | 3K | 4K |
| Retained Earnings | (136.34M) | (186.36M) | (249.5M) | (279.55M) | (330.58M) |
| Accumulated OCI | 0 | 0 | (0) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.9M | (12.32M) | (27.07M) | (25.89M) | (33.86M) |
| Total Debt | 0 | 1.96M | 1.6M | 23.63M | 34.44M |
| Net Debt | (30.3M) | (7.45M) | (10.18M) | 15.1M | 14M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.